Antidiabetics in Australia Market Forecast: Industry Research Report

Antidiabetics in Australia Market Forecast

Published Date: October 2009

Published By: Datamonitor

Page Count: 125

Order Code: R313-56415

Questions About This Report

E-mail a Colleague

Printable Page

Fax Your Order

Description

Table of Contents

Similar
Products

Introduction

Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now.

Reasons to Purchase

Identify key opportunities and threats that will impact the use and uptake of new and existing products
Quantify the future size and scope of the Australian antidiabetics market and predict the performance of key compounds
Understand critical success factors in growing and defending antidiabetic brand franchises from new entrants and generics

Please note: this is delivered as a Zip file.

Similar Products

• Prostate Cancer Drug Discoveries: What the Future Holds

Published Nov 2009 by Espicom Healthcare Intelligence

• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)

Published Nov 2009 by La Merie S.L.

• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)

Published Nov 2009 by La Merie S.L.

• Competitor Analysis: FGF-R Agonists and Antagonists

Published Nov 2009 by La Merie S.L.

• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis

Published Nov 2009 by Aruvian's R'search